Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Thu, 11.04.2024
Formycon AG
Press release // April 11, 2024
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
Commercial launch opens up additional key markets in Europe and North America, making FYB201 available in a total of 17 countries worldwide
Lucentis® biosimilar FYB201 is an effective and cost-effi [ … ]
Mon, 18.03.2024
Formycon AG
Press release // March 18, 2024
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
Munich, Germany – Formycon AG (FSE: FYB) and its commercialization partner Fresenius Kabi today announced the signing of a settlement agreement with Johnson & Johnson concerning the comme [ … ]
Mon, 11.03.2024
Formycon AG
Press release // March 11, 2024
FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
Commercialization partner MS Pharma wins government tender for Ranibizumab in Saudi Arabia
Commercial launch of FYB201/Ravegza® planned for second quarter of 2024
Further launches planned throughout 2024 to improve access [ … ]
Mon, 29.01.2024
Formycon AG
Press Release // January 29, 2024
Gedeon Richter becomes strategic investor of Formycon via equity investment
Already established trustful collaboration in contract development and manufacturing results in investment through takeover of 9.08% of shares via cash capital increase
Gross-proceeds in the amount of EUR 82.84 million to maintain Formyc [ … ]
Mon, 29.01.2024
Formycon AG
NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, PUBLICATION OR TRANSMISSION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
Disclosure of i [ … ]
Thu, 18.01.2024
Formycon AG
Press Release // January 18, 2024
Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023
Munich, Germany – Formycon AG (FWB: FYB) today announced that its commercialization partner, Coherus BioSciences, Inc. has released new sales figures for CIMERLI®1 (Ranibizumab-eqrn) in the US [ … ]
Thu, 04.01.2024
Formycon AG
Press Release // January 04, 2024
Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference
Munich, Germany – Formycon AG (FSE: FYB), a leading, independent developer of high-quality biosimilars, today announced that Formycon CEO Dr. Stefan Glombitza will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on T [ … ]
Wed, 27.12.2023
Formycon AG
Press Release // December 27, 2023
Formycon announces EMA acceptance of the MAA for FYB203, a biosimilar candidate to Eylea®(Aflibercept)
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Klinge Biopharma GmbH (“Klinge”) announce that the European Medicines Agency (“EMA”) has accepted the marketing authorization ap [ … ]
Thu, 07.12.2023
Formycon AG
Press Release // December 07, 2023
Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis®
Munich, Amsterdam, Zug, Toronto – Formycon AG, Polpharma Biologics Group BV, Bioeq AG and Teva Canada Ltd. jointly announce that Health Canada has granted the “Notice of Compliance” (NOC) for Ranopto®1 (Ranibizumab), a biosimilar [ … ]
Tue, 05.12.2023
Formycon AG
Press Release // December 05, 2023
Formycon announces participation in international Investor Conferences in Q1/2024
Munich/Martinsried – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced that members of the Management Board plan to be present at the following investor conferences in the first quarter of 2024:
J.P. Morgan Hea [ … ]